Form 4: Denali Therapeutics Director Nancy Thornberry Reports Stock and Option Transactions

Director Nancy Thornberry reports acquisition of stock and options in Denali Therapeutics on May 31, 2024.

Summary

• On May 31, 2024, Nancy Thornberry, a director of Denali Therapeutics Inc., reported transactions involving the company's stock and options.
• Thornberry acquired 5,967 shares of common stock represented by Restricted Stock Units (RSUs) at a price of $0.
• These RSUs vest upon the earlier of one year from the grant date or the day preceding the next annual meeting of stockholders.
• Thornberry also acquired 17,901 stock options with an exercise price of $18.56, which also vest under the same conditions as the RSUs.
• Following these transactions, Thornberry directly owns 18,680 shares of common stock, including 6,595 unvested RSUs, and 17,901 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing is a standard disclosure of insider transactions. The acquisitions could be interpreted as a positive sign, but it's a routine event.

Positives

• The acquisition of shares and options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, which can be informative for investors.

Stakeholder Impact

• The transactions may have a minor impact on shareholder sentiment, depending on how investors interpret the insider's actions.

Key Dates